HFE p.C282Y纯合子与肝脏恶性肿瘤风险的关联
女性中关联不显著。
要点
- 男性p.C282Y纯合子肝癌风险显著增加(HR 10.5)。
- 男性p.C282Y纯合子全因死亡风险轻度升高(HR 1.2)。
- 女性p.C282Y纯合子与肝癌及死亡关联不显著。
核心结论
- 男性HFE p.C282Y纯合子发生原发性肝癌和死亡的风险显著高于无HFE变异者,女性中未发现显著关联。
主要发现
- 男性p.C282Y纯合子至75岁原发性肝癌风险7.2%(95%CI 3.9%-13.1%),无变异男性为0.6%(95%CI 0.4%-0.7%)。
- 男性p.C282Y纯合子至75岁死亡风险19.5%(95%CI 15.8%-24.0%),无变异男性为15.1%(95%CI 14.7%-15.5%)。
临床怎么用
- 对男性p.C282Y纯合子应关注肝癌监测和早期干预。
- 女性p.C282Y纯合子的肝癌风险关联不显著,需个体化评估。
局限性
- 研究仅纳入欧洲裔参与者,结果外推需谨慎。
- 部分参与者缺乏初级保健数据,可能低估肝癌发生。
- 早期诊断和治疗对结局的影响尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hereditary hemochromatosis is predominantly caused by the HFE p.C282Y homozygous pathogenic variant. Liver carcinoma and mortality risks are increased in individuals with clinically diagnosed hereditary hemochromatosis, but risks are unclear in mostly undiagnosed p.C282Y homozygotes identified in community genotyping. OBJECTIVE: To estimate the incidence of primary hepatic carcinoma and death by HFE variant status. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 451 186 UK Biobank participants of European ancestry (aged 40-70 years), followed up from baseline assessment (2006-2010) until January 2018. EXPOSURES: Men and women with HFE p.C282Y and p.H63D genotypes compared with those with neither HFE variants. MAIN OUTCOMES AND MEASURES: Two linked co-primary outcomes (incident primary liver carcinoma and death from any cause) were ascertained from follow-up via hospital inpatient records, national cancer registry, and death certificate records, and from primary care data among a subset of participants for whom data were available. Associations between genotype and outcomes were tested using Cox regression adjusted for age, assessment center, genotyping array, and population genetics substructure. Kaplan-Meier lifetable probabilities of incident diagnoses were estimated from age 40 to 75 years by HFE genotype and sex. RESULTS: A total of 451 186 participants (mean [SD] age, 56.8 [8.0] years; 54.3% women) were followed up for a median (interquartile range) of 8.9 (8.3-9.5) years. Among the 1294 male p.C282Y homozygotes, there were 21 incident hepatic malignancies, 10 of which were in participants without a diagnosis of hemochromatosis at baseline. p.C282Y homozygous men had a higher risk of hepatic malignancies (hazard ratio [HR], 10.5 [95% CI, 6.6-16.7]; P < .001) and all-cause mortality (n = 88; HR, 1.2 [95% CI, 1.0-1.5]; P = .046) compared with men with neither HFE variant. In lifetables projections for male p.C282Y homozygotes to age 75 years, the risk of primary hepatic malignancy was 7.2% (95% CI, 3.9%-13.1%), compared with 0.6% (95% CI, 0.4%-0.7%) for men with neither variant, and the risk of death was 19.5% (95% CI, 15.8%-24.0%), compared with 15.1% (95% CI, 14.7%-15.5%) among men with neither variant. Among female p.C282Y homozygotes (n = 1596), there were 3 incident hepatic malignancies and 60 deaths, but the associations between homozygosity and hepatic malignancy (HR, 2.1 [95% CI, 0.7-6.5]; P = .22) and death (HR, 1.2 [95% CI, 0.9-1.5]; P = .20) were not statistically significant. CONCLUSIONS AND RELEVANCE: Among men with HFE p.C282Y homozygosity, there was a significantly increased risk of incident primary hepatic malignancy and death compared with men without p.C282Y or p.H63D variants; there was not a significant association for women. Further research is needed to understand the effects of early diagnosis and treatment.
引用
- Atkins JL, Pilling LC, Masoli JAH, et al. Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy. JAMA. 2020. PMID: 33231665. doi:10.1001/jama.2020.21566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。